SignaCor

Belfast, United Kingdom

SignaCor is a clinical-stage biotech company exploring therapeutics for cardiac disorders, specifically hypertrophic cardiomyopathy.

$332K raised

Mar 2026

Seed

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has SignaCor raised?

SignaCor has raised $332K in total funding. The most recent round was Seed. The last funding was announced in March 2026.

Who are SignaCor's investors?

SignaCor's investors include Zinc.

Where is SignaCor headquartered?

SignaCor is headquartered in Belfast, United Kingdom.

What does SignaCor do?

SignaCor is a clinical-stage biotech company exploring therapeutics for cardiac disorders, specifically hypertrophic cardiomyopathy.

What stage is SignaCor at?

SignaCor is at the Seed stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated March 9, 2026.

MLA

"SignaCor — Funding & Investors." VCBacked, March 9, 2026, https://www.vcbacked.co/company/signacor. Accessed July 2, 2026.

APA

VCBacked. (2026). SignaCor — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/signacor

Wikipedia (cite web)

{{cite web |title=SignaCor — Funding & Investors |url=https://www.vcbacked.co/company/signacor |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated March 9, 2026.